Bixiye
P27-17 New Drug-Related Prior Authorization (PA) with Quantity Limit (QL) Criteria: Antifungal Agents
Taariikhda uu dhaqangalayo Barnaamijka: May 25, 2017
Natiijooyinka Raadinta
Soo bandhiga 2611 - 2620 ee natiijooyinka 4296
Bixiye
P58-17 New Drug-Related Prior Authorization with Quantity Limit Criteria: Topical Doxepin
Taariikhda uu dhaqangalayo barnaamijka: Okt 24, 2017
Bixiye
P59-16 Organization Determination Additions for Platinum Blue - Effective January 23, 2017
Taariikhda uu dhaqangalayo Barnaamijka: Des 08, 2016
Bixiye
P51-16 Addition of a Drug (Belviq XR) to the Weight Loss Agents Prior Authorization with Quantity Limit Program
Taariikhda uu dhaqangalayo barnaamijka: Okt 28, 2016
Bixiye
QP92-24 Process Update for Post-Acute Care Authorizations managed by eviCore Healthcare
Taariikhda uu dhaqangalayo Barnaamijka: Des 23, 2024
Bixiye
QP91-24 Commercial Pharmacy Benefit Update: New and Revised Drug-Related Prior Authorization (PA) Requirement Notification, Effective February 1, 2025
Taariikhda uu dhaqangalayo Barnaamijka: Des 23, 2024
Bixiye
QP90-24 MHCP Pharmacy Benefit Update: New and Revised Drug-Related Prior Authorization (PA) Requirement Notification, Effective January 1, 2025
Taariikhda uu dhaqangalayo Barnaamijka: Des 23, 2024
Bixiye
QP93-24 Blue Cross and Blue Shield of Minnesota Collaborating with Maven
Taariikhda uu dhaqangalayo Barnaamijka: Des 23, 2024
Bixiye
QP94-24 MHCP Pharmacy Benefit Exclusion for Darzalex Faspro®, Supprelin® LA and Visudyne®
Taariikhda uu dhaqangalayo Barnaamijka: Des 23, 2024
Bixiye
QP96-24 Prescription Drug Electronic Prior Authorization (ePA) Submission Process Update
Taariikhda uu dhaqangalayo Barnaamijka: Des 23, 2024